Ameritas Investment Partners, Inc. Chemo Centryx, Inc. Transaction History

Ameritas Investment Partners, Inc.

$2.98 Billion
Q3 2024

Shares

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$22.17 - $51.8 $4,766 - $11,137	215 Added 4.54%	4,955 $255,000
Q2 2022 Aug 12, 2022	BUY	$15.36 - $27.51 $10,859 - $19,449	707 Added 17.53%	4,740 $117,000
Q1 2021 May 14, 2021	SELL	$49.53 - $68.4 $9,509 - $13,132	-192 Reduced 4.54%	4,033 $207,000
Q3 2020 Nov 13, 2020	BUY	$46.35 - $61.69 $13,719 - $18,260	296 Added 7.53%	4,225 $232,000
Q2 2020 Aug 05, 2020	BUY	$38.58 - $65.07 $10,416 - $17,568	270 Added 7.38%	3,929 $226,000
Q1 2020 May 13, 2020	BUY	$32.73 - $50.78 $4,909 - $7,617	150 Added 4.27%	3,659 $147,000
Q2 2019 Aug 14, 2019	BUY	$8.31 - $14.85 $11,542 - $20,626	1,389 Added 65.52%	3,509 $33,000
Q2 2017 Aug 15, 2017	BUY	N/A	2,120	2,120 $20,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ameritas Investment Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ameritas Investment Partners, Inc. with notifications on news.